Skip to main content
PMC home page
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2018 Nov 6;11:7865–7872. doi: 10.2147/OTT.S176818

Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro

Tao Jiang 1,✉, Min-Li Zhou 2, Jun Fan 3
PMCID: PMC6228052  PMID: 30464533

Abstract

Background

The mechanism of chemoresistance remains unknown. Here, we investigated if glucose transporter-1 (GLUT-1) and PI3K/Akt pathways are associated with the sensitivity to cisplatin in Hep-2 laryngeal carcinoma cells and whether the inhibition of GLUT-1 and the PI3K/Akt pathways enhances the chemosensitivity of Hep-2 cells.

Method

The effects of inhibiting GLUT-1 by a GLUT-1 siRNA, and PI3K/Akt by Ly294002, on cisplatin-induced effects were assessed in vitro.

Results

GLUT-1 siRNA and cisplatin showed a synergistic effect in inhibiting the proliferation of Hep-2. LY294002 and cisplatin also showed a synergistic effect in inhibiting the proliferation of Hep-2. GLUT-1 siRNA, LY294002 and cisplatin effectively inhibited the mRNA expressions and protein expressions of GLUT-1, Akt, PI3k and HIF-1α in Hep-2 cells. Furthermore, GLUT-1 siRNA and cisplatin demonstrated a synergism to inhibit the mRNA expression of HIF-1α. Moreover, it was found in this study that GLUT-1 siRNA, LY294002 and cisplatin induced the suppression of the cell cycle at G1/G2 and the increasing of apoptosis in Hep-2 cells.

Conclusion

This study showed that inhibiting GLUT-1, by a GLUT-1 siRNA and inhibiting PI3K/Akt by Ly294002, could suppress the proliferation of Hep-2 alone and together with cisplatin synergistically, which demonstrated the potentials to treat laryngeal carcinoma in the future therapy. Additionally, the synergistic effect between LY294002 and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt, PI3k and HIF-1α; the synergistic effect between GLUT-1 siRNA and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt and PI3k and might be more or less related to HIF-1α.

Keywords: laryngeal carcinoma, RNA interference, glucose transporter-1, PI3K/Akt pathway, cisplatin, chemosensitivity

Introduction

Although promising treatments preserving laryngeal function, including chemotherapy and radiotherapy, have been advanced, the overall survival rate of patients with laryngeal carcinoma remains poor.1,2 One possible mechanism may be the development of chemoradioresistance in laryngeal carcinoma. Studies have demonstrated that hypoxia plays a key role in laryngeal carcinoma radioresistance:3–6 1) Glucose transporter-1 (GLUT-1), as an important hypoxic marker, has also been found to have an important role in laryngeal carcinoma radiosensitivity, and inhibition of GLUT-1 expression may enhance the radiosensitivity of laryngeal carcinoma;2,6–9 2) HIF-1α, as another important hypoxic marker, has also been found to have an important role in laryngeal carcinoma radiosensitivity, and inhibition of HIF-1α expression may enhance the radiosensitivity of laryngeal carcinoma.2 However, whether GLUT-1 or HIF-1α is involved in chemosensitivity in laryngeal carcinoma remains unknown.

The phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway has been demonstrated to play an important role in the regulation of GLUT-1 and HIF-1α expressions.10,11 The PI3K/Akt pathway is involved in the chemoradiosensitivity of other malignant tumors.12–14 In laryngeal carcinoma, we found that GLUT-1 expression, via the PI3K/Akt pathway, plays a role in radiosensitivity, and co-inhibits the GLUT-1 expression and the PI3K/Akt pathway enhanced the radiosensitivity of laryngeal carcinoma.6,7 However, whether the expression of GLUT-1 or HIF-1α, via the PI3K/Akt pathway, is also involved in the chemosensitivity of laryngeal carcinoma is still unknown.

Cisplatin is a frequently-used chemotherapeutic drug for head and neck carcinomas; it may inhibit DNA replication and harm cell membrane structures.15,16 However, the development of resistance limits the clinical utility of cisplatin.17–19 The expression of GLUT-1 was shown to be related to cisplatin resistance. Moreover, inhibition of GLUT-1 expression may enhance sensitivity to cisplatin.17–19 Some research studies have also demonstrated that the PI3K/Akt pathway may be responsible for cisplatin resistance, and suppression of the PI3K/Akt pathway may enhance some solid tumors to be sensitive to cisplatin.20–22 Only our previous study examined the roles of expression of GLUT-1 and the PI3K/Akt pathway in cisplatin resistance of laryngeal cancer.17 We found that resistance to or insensitivity of Hep-2 cells to cisplatin may be related to the expression of GLUT-1, p-Akt protein and apigenin, which is a natural phytoestrogen flavonoid, may suppress the GLUT-1 expression and p-Akt expression non-specifically to improve the sensitivity of cisplatin.17 For HIF-1α, it was found that Sentrin/SUMO-specific protease 1 (SENP1) positively regulated the expression of HIF-1α by deSUMOylation and weakened the sensitivity of hypoxic ovarian cancer cells to cisplatin, indicating that SENP1 is a positive regulator of HIF-1α and plays a negative role in ovarian cancer chemotherapy.23

In this study, we systematically investigated the possible synergistic effects between inhibiting GLUT-1 by a GLUT-1 siRNA and cisplatin and between inhibiting PI3K/Akt by the inhibitor Ly294002 and cisplatin on the proliferation, the expressions of GLUT-1, Akt, PI3K and HIF-1α in laryngeal carcinoma cells (Hep-2), to help in the development of the better therapy for laryngeal carcinoma.

Materials and methods

Ethics statement

This investigation was conducted in accordance with the appropriate ethical standards. It was approved by a review board of Yinzhou People’s Hospital of Ningbo City Zhejiang Province, China.

Reagents

The Hep-2 laryngeal carcinoma cell line was obtained from the Cell Research Institute of the Chinese Academy of Sciences (Shanghai, China). Cisplatin and Ly294002 were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). The reverse transcription (RT) “Fast Quant RT” kit (supplied with gDNase; cat. no #KR106-2), Trizol (cat: ET111-01), chloroform, isopropyl alcohol, and RNA dissolving liquid (cat: ET111-02) were purchased from Biogot Technology, Co., Ltd. (Nanjing, China). A primary antibody against GLUT-1 was purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). Secondary antibodies, donkey anti-rabbit and donkey anti-mouse, cell lysis reagents, the SuperSignal West Femto Kit and phenylmethanesulfonyl fluoride were purchased from Pierce (Rockford, IL, USA). Primers and Lipofectamine 2000 were purchased from Thermo Fisher Scientific (Waltham, MA, USA). The sequence of the entire coding region of GLUT-1 was obtained from GenBank, and primers were designed using the ClustalX and Omega 2.0 Applied Software. The Cell Counting Kit-8 (CCK-8) kit was purchased from Dojindo (Tokyo, Japan).

Design and transfection of GLUT-1 siRNA

GLUT-1 siRNA was used to silence GLUT-1 expression in Hep-2 cells. siRNAs targeting the GLUT-1 sequence were designed by Shanghai GenePharma Co., Ltd. (Shanghai, China). The GLUT-1 or negative control (NC) siRNAs were then cloned into viral vectors, and lentiviruses carrying GLUT-1 and NC siRNAs were synthesized by Shanghai GenePharma Co., Ltd. GLUT-1 siRNA was transiently transfected into Hep-2 cells to deplete GLUT-1 expression. The efficiency of transient transfection was estimated with the fluorescence in situ RNA hybridization method and the brief was: 1) after the transient transfection, the cells were washed with PBS and fixed with paraformaldehyde; 2) the fixed cells were washed and penetrated with Triton-X-100; 3) the resultant was then washed with PBS and incubated with the solution containing the probe with the fluorescent dye (6-carboxy-fluorescein); 4) after washing, the cells were observed under the inverted fluorescent microscope; 5) the transfection efficiency was estimated according to the range and intensity of the fluorescent signal. In this way, we found that the transfection efficiency was 65%–80%. Screening and identification of transfectants were achieved using real-time RT polymerase chain reaction (RT2-PCR).

Groups

In total, the following eight groups were analyzed: Hep-2, Hep2-siRNANC, Hep2-siRNAGLUT-1, Hep2+LY294002, Hep-2+cisplatin, Hep2-siRNANC+cisplatin, Hep2-siRNAGLUT-1+ cisplatin, and Hep-2+Ly294002+cisplatin.

Cell culturing

Hep-2 cells were cultured in 10% FBS and RPMI 1640 medium (Thermo Fisher Scientific), 2 mM L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin at 37°C in a 5% CO2 atmosphere. The cells were digested in 0.25% trypsin +0.02% EDTA. Cells were trypsinized and harvested after reaching 80%–90% confluence.

GLUT-1 siRNA transfection, treatment with cisplatin and Ly294002

Hep-2 cells were seeded in 96-well plates 24 hours before transfection, and 2 mL RPMI 1640 medium was added. Upon reaching 60%–70% confluency, the cells were used in experiments. Pure GLUT-1 siRNA (4 µg) and control siRNA were diluted in 250 µL Opti-MEMI Reduced Serum medium. Lipofectamine 2000 was mixed gently and diluted in 250 µL Opti-MEMI Reduced Serum medium for 5 minutes. Diluted siRNA-GLUT-1 or siRNANC was mixed gently with Lipofectamine 2000 for 20 minutes at room temperature. Then, the diluted siRNA-GLUT-1 or siRNANC and Lipofectamine 2000 were added to cultured Hep-2 cells at room temperature and cultured for 8 hours. The Hep-2 cells were cultured for a further 24 hours after refreshing the medium, and 20 µM LY294002 and 3 µg/mL cisplatin were added for another 24 hours and 48 hours, respectively.

CCK-8 assay

Cells from each group were cultured with 10 µL CCK solution for 2 hours. The absorption at 450 nm was measured using a Spectra Plus microplate reader (Molecular Devices LLC, Sunnyvale, CA, USA). The relative cell inhibition rate (IR) (%) was calculated by the following formula: 100% - (sample absorption/control mean absorption) ×100%.

Analysis of apoptosis and cell cycle by flow cytometry

Flow cytometry was performed as described previously.8 Cell cultures from each group were digested with trypsin without EDTA and then centrifuged (2,000 rpm). The cells were collected and washed with 500 µL PBS. Then, 400 µL Binding Buffer (M3036) was added. Next, 5 µL annexin V-FITC (M3031) was added, and the mixture was incubated for 5 minutes in the dark. The data were analyzed using ModFit LT software (Becton Dickinson, Mountain View, CA, USA). Each experiment was performed in triplicate.

Detection of GLUT-1, AKT, PI3K, and HIF-1α mRNA expression by RT2-PCR

RT2-PCR was performed as described previously.8,17 Total RNA was extracted from cell cultures from each group, and mRNA was reverse transcribed. The mRNA RT reaction contained 2 µL RNA template and 5 µL 25 µM primers, which were heated to 70°C for 5 minutes before adding to the following: 10 µL 2× RT buffer, 3 µL 375 nM dNTPs, 0.4 µL 4 U/µL MMLV reverse transcriptase, and 0.15 µL 0.3 U/µL RNasin before incubation at 37°C for 60 minutes and 85°C for 10 minutes. Then, RT2-PCR was set up containing 20 µL mRNA, 10 µL 2× quantification PCR Master Mix, 0.08 µL 0.08 µM forward primer, 0.08 µL 0.08 µM reverse primer, 2 µL template, 0.4 µL Taq DNA polymerase, and deionized water. The RT2-PCR reaction conditions were denaturation at 95°C for 3 minutes, followed by 40 cycles of 95°C for 30 seconds and 62°C for 40 seconds. Each reaction was run three times. GLUT-1, AKT, PPIK, HIF-1α and GAPDH forward and reverse primers were 5′-GTCAACACGGCCTTCACTG-3′ and 5′-GGTCATGAGTATGGCACAACC-3′ for GLUT-1, 5′-GCAGCACGTGTACGAGAAGA-3′ and 5′-GGTGTCAGTCTCCGACGTG-3′ for AKT, 5′-GGGGATGATTTACGGCAAGATA-3′ and 5′-CACCACCTCAATAAGTCCCACA-3′ for PPIK, 5′-GAAAGCGCAAGTCTTCAAAG-3′ and 5′-TGGGTAGGAGATGGAGATGC-3′ for HIF-1α, and 5′-TGTTGCCATCAATGACCCCTT-3′ and 5′-CTCCCACGACGTACTCAGCG-3′ for GAPDH (control), respectively. The sizes of the PCR products were 111 bp (GLUT-1), 67 bp (AKT), 144 bp (PI3K), 167 bp (HIF-1α), and 202 bp (GAPDH).

Detection of GLUT-1, AKT, PI3K, and HIF-1α protein levels in Hep-2 cells

Briefly,17 protein samples from cell cultures from each group were added to 4× sodium dodecyl sulfate (SDS) buffer, boiled for 10 minutes, and centrifuged (1,200 rpm, 1 minute). The proteins were separated by SDS-polyacrylamide gel electrophoresis. After electrophoresis, the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (EMD Millipore, Billerica, MA, USA). Primary antibodies against the following proteins were added to the membrane and incubated at 4°C overnight: GLUT-1 (1:800; Proteintech Group, Chicago, IL, USA), p-AKT (1:800; Proteintech Group), AKT (1:800; Proteintech Group), PI3K (1:800; Proteintech Group), HIF-1α (1:800; Proteintech Group) and GAPDH (1:800; Proteintech Group). The PVDF membrane was washed with TBST buffer three times for 10 minutes. Secondary antibodies were added and incubated, and the membrane was washed with PBST buffer three times. The PVDF membrane was placed on a color plate, incubated with solutions A and B from the enhanced chemiluminescence assay kit (Beyotime Biological Technology Co. Ltd., Nanjing, China), and exposed to X-ray film. Semi-quantitatively using the ChemiDoc XRS + System (Bio-Rad Laboratories Inc., Hercules, CA, USA) analyzed the expression of proteins.

Statistical analyses

Data were presented in mean ± SD. SPSS software (ver. 24.0 for Windows; SPSS Inc., Chicago, IL, USA) was used for all statistical analyses: 1) for the comparison between two groups, the Student’s independent sample t-test was used; 2) for the analysis of the synergistic effect between two factors, the factor analysis was used. P-value less than 0.05 was considered to be statistically significant.

Results

Effects of siRNA-GLUT-1 and LY294002 on the proliferation of Hep-2 cells after treatment with cisplatin

Before treatment with cisplatin, the survival rates of cells in the siRNA-GLUT-1 and LY294002 groups were decreased significantly at 24 hours and 48 hours compared with the control group and the siRNA-NC groups (P<0.05; Figure 1). The proliferation of cells in each group was decreased markedly at 24 hours and 48 hours treated by cisplatin compared with before treatment (P<0.05). The survival rates of cells in the siRNA-GLUT-1+ cisplatin and LY294002+ cisplatin groups were decreased significantly at 24 hours and 48 hours compared with cells in the siRNA-GLUT-1 group, LY294002 and cisplatin group, respectively (for all, P<0.05; Figure 1). The factor analyses showed that for the inhibitory effect on the proliferation of Hep-2, there were synergistic effects between siRNA-GLUT-1 and cisplatin and between LY294002 and cisplatin. These findings revealed that siRNA-GLUT-1 and LY294002 could enhance the inhibitory effect of cisplatin on the proliferation of Hep-2 cells, respectively.

Figure 1.

Figure 1

Open in a new tab

The survival rates of cells in the siRNA-GLUT-1+ cisplatin and LY294002+ cisplatin groups were decreased significantly at 24 hours (A) and 48 hours (B) compared with cells in the cisplatin group.

Effects of siRNA-GLUT-1 and LY294002 on apoptosis and cell cycle in Hep-2 cells after treatment with cisplatin

Before the cisplatin treatment, the apoptotic rates of cells in the siRNA-GLUT-1 and LY294002 groups were increased markedly at 24 hours and 48 hours compared with the Hep-2 cell and siRNA-NC groups (P<0.05; Figure 2). The early apoptotic cell number was increased markedly in the siRNA-GLUT-1 group, and that of late apoptotic cells was increased markedly in the LY294002 group. After the cisplatin treatment, the apoptotic rates in both groups were increased significantly at 24 hours and 48 hours (P<0.05; Figure 2). The apoptotic rates of cells in the siRNA-GLUT-1+ cisplatin and LY294002+ cisplatin groups were increased markedly at 24 hours and 48 hours compared with cells in the cisplatin group (P<0.05; Figure 2). These findings show that siRNA-GLUT-1 and LY294002 enhance the cisplatin-increased apoptotic rate in laryngeal carcinoma Hep-2 cells.

Figure 2.

Figure 2

Open in a new tab

The apoptotic rates of cells in the siRNA-GLUT-1+ cisplatin and LY294002+ cisplatin groups were increased significantly at 24 hours and 48 hours compared with cells in the cisplatin group.

After the cisplatin treatment, the population of cells in the G1/G2 phase was reduced markedly. siRNA-GLUT-1+ cisplatin significantly decreased the population of cells in the G1/G2 phase compared with cisplatin or siRNA-GLUT-1 (P<0.01; Figure 3). The population of Hep-2 cells treated with LY294002+cisplatin in the G1/G2 phase was increased markedly than those in the untreated Hep-2 cells. LY294002 markedly reduced the population of cells in the G1/G2 phase compared with cisplatin or LY294002 (P<0.05; Figure 3).

Figure 3.

Figure 3

Open in a new tab

siRNA-GLUT-1+ cisplatin significantly decreased the number of cells in the G1/G2 phase compared with cisplatin or siRNA-GLUT-1, and LY294002 significantly decreased the number of cells in the G1/G2 phase compared with cisplatin or LY294002.

The abovementioned findings suggested that the synergistic effects between siRNA-GLUT-1 and cisplatin and between LY294002 and cisplatin might be at least partly from their synergistic effects on the apoptotic rate and the G1/G2 cell cycle arrest.

Effects of siRNA-GLUT-1 and LY294002 on GLUT-1, p-Akt, PI3K, and HIF-1α mRNA levels in Hep-2 cells after treatment with cisplatin

siRNA-GLUT-1, cisplatin, siRNAGLUT-1+cisplatin, and LY294002+cisplatin significantly inhibited GLUT-1 and HIF-1α mRNA expression in Hep-2 cells compared with the control group (P<0.05; Figure 4A and B). siRNAGLUT-1+ cisplatin and LY294002+cisplatin significantly inhibited GLUT-1 and HIF-1α mRNA expression in Hep-2 cells compared with the cisplatin group (P<0.001; Figure 4A and B).

Figure 4.

Figure 4

Open in a new tab

Effects of siRNA-GLUT-1 and LY294002 on GLUT-1, p-Akt, PI3K, and HIF-1α mRNA levels in Hep-2 cells after treatment with cisplatin.

Notes: siRNAGLUT-1+cisplatin and LY294002+cisplatin significantly inhibited GLUT-1 (A) and HIF-1α mRNA (B) expression in Hep-2 cells compared with the cisplatin group. (C): LY294002+cisplatin significantly inhibited p-AKT mRNA expression in Hep-2 cells compared with cisplatin alone and LY294002 alone. (D). LY294002+cisplatin significantly inhibited PI3K mRNA expression in Hep-2 cells compared with cisplatin alone.

LY294002 and LY294002+cisplatin significantly inhibited p-AKT mRNA expression in Hep-2 cells compared with the control group (P=0.03 and 0.019, respectively; Figure 4C). LY294002+cisplatin significantly inhibited p-AKT mRNA expression in Hep-2 cells compared with cisplatin alone and LY294002 alone (P=0.001 and 0.001, respectively; Figure 4C). siRNAGLUT-1, cisplatin and siRNAGLUT-1+ cisplatin did not effect the expression of p-AKT mRNA in Hep-2 cells compared with the control (P>0.05).

LY294002 and LY294002+cisplatin significantly inhibited PI3K mRNA expression in Hep-2 cells compared with the control group (P<0.05; Figure 4D). LY294002+cisplatin significantly inhibited PI3K mRNA expression in Hep-2 cells compared with cisplatin alone (P=0.007; Figure 4D). siRNA-GLUT-1 and cisplatin did not effect the expression of PI3K mRNA in Hep-2 cells compared with the control group (P>0.05).

The factor analyses revealed that there were no synergistic effects between LY294002 and cisplatin on the mRNA expression of GLUT-1, Akt, PI3K and HIF-1α and there were no synergistic effects between siRNAGLUT-1 and cisplatin on the mRNA expression of GLUT-1, Akt and PI3K and there were synergistic effects between siRNAGLUT-1 and cisplatin on the mRNA expression of HIF-1α.

Effects of siRNA-GLUT-1 and LY294002 on GLUT-1, p-Akt, PI3K, and HIF-1α protein levels in Hep-2 cells after treatment with cisplatin

siRNA-GLUT-1, cisplatin, siRNAGLUT-1+cisplatin and LY294002+cisplatin inhibited GLUT-1 and HIF-1α protein levels in Hep-2 cell compared with the control group (Figure 5). siRNAGLUT-1+cisplatin and LY294002+cisplatin significantly inhibited GLUT-1 and HIF-1α protein levels in Hep-2 cells compared with cisplatin alone (Figure 5). LY294002 and LY294002+cisplatin inhibited p-AKT and PI3K protein levels in Hep-2 cells compared with the control group. LY294002+cisplatin significantly inhibited p-AKT and PI3K protein levels in Hep-2 cells compared with cis-platin alone and LY294002 alone (Figure 5).

Figure 5.

Figure 5

Open in a new tab

Effects of siRNA-GLUT-1 and LY294002 on GLUT-1, p-Akt, PI3K and HIF-1α protein levels in Hep-2 cells after treatment with cisplatin.

Discussion

The rapid proliferation of malignant tumors requires high levels of energy. Warburg effect is an anomalous characteristic of cancer cells, in which they consume a large amount of glucose and favor aerobic glycolysis over oxidative phosphorylation even in the presence of oxygen.24 GLUT-1 and HIF-1α are key enzymes that mediate glucose metabolism in tumorigenesis.25,26 Overexpression of GLUT-1 has been demonstrated to be associated with recurrence, poor survival, metastasis and chemo-radioresistance in malignant tumors,27,28 including laryngeal carcinoma.29,30 Our previous studies have found that there were relationships between GLUT-1-expression and radioresistance of laryngeal carcinoma and that inhibition the expression of GLUT-1 may enhance the radiosensitivity of laryngeal carcinoma.2,6–9 The mechanism may involve the activated PI3K/Akt pathway, which regulates GLUT-1expression. It has been found that specific inhibitors of the PI3K/Akt pathway (eg, Ly294002, Wortmannin) reduce GLUT-1expression and improve the radiosensitivity of laryngeal carcinoma. There is only one previous report about the expression of GLUT-1 and chemoresistance in laryngeal cancer.17 However, effect of the PI3K/Akt pathway on GLUT-1expression and its involvement in the GLUT-1-induced chemoresistance of laryngeal carcinoma were unclear.

Several studies have investigated the potential mechanism of GLUT-1-induced chemosensitivity. GLUT-1 had been associated with markers of intrinsic chemosensitivity, such as glutathione-s-transferase-π, P-glycoprotein and multidrug resistance-associated protein.31 Shimanish et al showed that specific inhibition of GLUT-1 expression by siRNAs enhanced the sensitivity of oral squamous cell carcinoma to cisplatin, and the mechanism may involve HIF-1α-mediated GLUT-1 and glycolytic enzyme expression.18 However, another study showed that overexpression of GLUT-1 did not involve a corresponding increase in glycolytic enzyme levels regulated by HIF-1 but was associated with higher levels of phosphodiester related to phospholipid metabolism, suggesting that the mechanism of GLUT-1-regulated chemoresistance may involve increased cell turnover.32

In the present study, results showed that siRNA GLUT-1 significantly inhibited Hep-2 cell proliferation, apoptosis and numbers in G1/G2 and significantly enhanced cisplatin sensitivity in Hep-2 cells. LY294002 also enhanced cisplatin sensitivity in Hep-2 cells. Next, we investigated the mechanism by which GLUT-1 siRNA and LY294002 enhanced the cisplatin sensitivity of Hep-2 laryngeal carcinoma cells. The results revealed that there were no synergistic effects between LY294002 and cisplatin on the mRNA expression of GLUT-1, Akt, PI3K and HIF-1α and there were no synergistic effects between siRNAGLUT-1 and cisplatin on the mRNA expression of GLUT-1, Akt and PI3K and there were synergistic effects between siRNAGLUT-1 and cisplatin on the mRNA expression of HIF-1α.

Conclusion

This study showed that inhibiting GLUT-1, by a GLUT-1 siRNA, and PI3K/Akt, by the inhibitor Ly294002, could suppress the proliferation of Hep-2 alone and together with cisplatin synergistically, which demonstrated the potentials to treat laryngeal carcinoma in the future therapy. Additionally, the synergistic effect between LY294002 and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt, PI3k and HIF-1α; the synergistic effect between GLUT-1 siRNA and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt and PI3k and might be more or less related to HIF-1α.

Acknowledgments

This study was funded by Technology Department of Yinzhou, Ningbo City, Zhejiang Province, China (grant no 2014-99).

Footnotes

Author contributions

TJ and M-LZ designed the experiments and wrote the manuscript. JF carried out the experiments and participated in result interpretation; all authors revised the manuscript. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi: 10.3322/caac.21387. [DOI] [PubMed] [Google Scholar]
  • 2.Shen LF, Zhao X, Zhou SH, et al. In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1α by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT. Oncotarget. 2017;8(21):34709–34726. doi: 10.18632/oncotarget.16671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang M, Li X, Qu Y, Xu O, Sun Q. Hypoxia promotes radioresistance of CD133-positive Hep-2 human laryngeal squamous carcinoma cells in vitro. Int J Oncol. 2013;43(1):131–140. doi: 10.3892/ijo.2013.1929. [DOI] [PubMed] [Google Scholar]
  • 4.Min JW, Kim KI, Kim HA, et al. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem Biophys Res Commun. 2013;440(1):137–142. doi: 10.1016/j.bbrc.2013.09.041. [DOI] [PubMed] [Google Scholar]
  • 5.de Jong MC, Ten Hoeve JJ, Grénman R, et al. Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients. Clin Cancer Res. 2015;21(24):5630–5638. doi: 10.1158/1078-0432.CCR-15-0454. [DOI] [PubMed] [Google Scholar]
  • 6.Luo XM, Xu B, Zhou ML, et al. Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo. PLoS One. 2015;10(11):e0143306. doi: 10.1371/journal.pone.0143306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bao YY, Zhou SH, Lu ZJ, Fan J, Huang YP. Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo. Oncol Rep. 2015;34(4):1805–1814. doi: 10.3892/or.2015.4158. [DOI] [PubMed] [Google Scholar]
  • 8.Yan SX, Luo XM, Zhou SH, et al. Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. Int J Med Sci. 2013;10(10):1375–1386. doi: 10.7150/ijms.6855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Luo XM, Zhou SH, Fan J. Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res. 2010;38(6):1885–1892. doi: 10.1177/147323001003800601. [DOI] [PubMed] [Google Scholar]
  • 10.Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008;37(4):426–431. doi: 10.1097/MPA.0b013e3181735ccb. [DOI] [PubMed] [Google Scholar]
  • 11.Zhang W, Zhang JQ, Meng FM, Xue FS. Dexmedetomidine protects against lung ischemia-reperfusion injury by the PI3K/Akt/HIF-1α signaling pathway. J Anesth. 2016;30(5):826–833. doi: 10.1007/s00540-016-2214-1. [DOI] [PubMed] [Google Scholar]
  • 12.Chen B, Tan Y, Liang Y, et al. Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells. Oncol Lett. 2017;13(1):423–428. doi: 10.3892/ol.2016.5430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pan F, Mao H, Bu F, et al. Sp1-mediated transcriptional activation of miR-205 promotes radioresistance in esophageal squamous cell carcinoma. Oncotarget. 2017;8(4):5735–5752. doi: 10.18632/oncotarget.13902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chang L, Graham PH, Ni J, et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 2015;96(3):507–517. doi: 10.1016/j.critrevonc.2015.07.005. [DOI] [PubMed] [Google Scholar]
  • 15.Wang J, Wu Y, Gao W, et al. Identification and characterization of CD133+CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer. 2017;8(3):497–506. doi: 10.7150/jca.17444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li D, Zhou L, Huang J, Xiao X. Effect of multidrug resistance 1/P-glycoprotein on the hypoxia-induced multidrug resistance of human laryngeal cancer cells. Oncol Lett. 2016;12(2):1569–1574. doi: 10.3892/ol.2016.4749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Xu YY, Wu TT, Zhou SH, et al. Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study. Int J Clin Exp Pathol. 2014;7(7):3938–3947. [PMC free article] [PubMed] [Google Scholar]
  • 18.Shimanishi M, Ogi K, Sogabe Y, et al. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia. J Oral Pathol Med. 2013;42(5):382–388. doi: 10.1111/jop.12028. [DOI] [PubMed] [Google Scholar]
  • 19.Wang YD, Li SJ, Liao JX. Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin. Technol Cancer Res Treat. 2013;12(6):525–535. doi: 10.7785/tcrt.2012.500343. [DOI] [PubMed] [Google Scholar]
  • 20.Lin Q, Wang Y, Chen D, Sheng X, Liu J, Xiong H. Cisplatin regulates cell autophagy in endometrial cancer cells via the PI3K/AKT/mTOR signalling pathway. Oncol Lett. 2017;13(5):3567–3571. doi: 10.3892/ol.2017.5894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shi H, Pu J, Zhou XL, Ning YY, Bai C. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Tumour Biol. 2017;39(5):1010428317697568. doi: 10.1177/1010428317697568. [DOI] [PubMed] [Google Scholar]
  • 22.Liu T, Li R, Zhao H, et al. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma. Oncotarget. 2016;7(41):66851–66864. doi: 10.18632/oncotarget.11694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ao Q, Su W, Guo S, Cai L, Huang L. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α. Sci Rep. 2015;5:16396. doi: 10.1038/srep16396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Pereira KM, Chaves FN, Viana TS, et al. Oxygen metabolism in oral cancer: HIF and GLUTs (Review) Oncol Lett. 2013;6(2):311–316. doi: 10.3892/ol.2013.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yoon SO, Jeon TJ, Park JS, et al. Analysis of the roles of glucose transporter 1 and hexokinase 2 in the metabolism of glucose by extrahepatic bile duct cancer cells. Clin Nucl Med. 2015;40(3):e178–e182. doi: 10.1097/RLU.0000000000000640. [DOI] [PubMed] [Google Scholar]
  • 26.Wang HJ, Hsieh YJ, Cheng WC, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism. Proc Natl Acad Sci U S A. 2014;111(1):279–284. doi: 10.1073/pnas.1311249111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Chikamoto A, Inoue R, Komohara Y, et al. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. Ann Surg Oncol. 2017;24(7):2040–2046. doi: 10.1245/s10434-017-5799-1. [DOI] [PubMed] [Google Scholar]
  • 28.Chen X, Lu P, Zhou S, Zhang L, Zhao JH, Tang JH. Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis. Oncotarget. 2017;8(8):13206–13213. doi: 10.18632/oncotarget.14570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zhou S, Wang S, Wu Q, Fan J, Wang Q. Expression of glucose transporter-1 and -3 in the head and neck carcinoma – the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec. 2008;70(3):189–194. doi: 10.1159/000124293. [DOI] [PubMed] [Google Scholar]
  • 30.Wu XH, Chen SP, Mao JY, Ji XX, Yao HT, Zhou SH. Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. Oncol Lett. 2013;5(1):261–266. doi: 10.3892/ol.2012.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Mao ZP, Zhao LJ, Zhou SH, Liu MQ, Tan WF, Yao HT. Expression and significance of glucose transporter-1, P-glycoprotein, multidrug resistance-associated protein and glutathione S-transferase-π in laryngeal carcinoma. Oncol Lett. 2015;9(2):806–810. doi: 10.3892/ol.2014.2752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Evans A, Bates V, Troy H, et al. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol. 2008;61(3):377–393. doi: 10.1007/s00280-007-0480-1. [DOI] [PubMed] [Google Scholar]

Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES